Jeffrey N. Martin, MD, MPH

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Jeffrey N. Martin, MD, MPH

Professor of Epidemiology and Biostatistics, UCSF; Attending Physician, San Francisco General Hospital

martin@psg.ucsf.edu

Phone: (415) 514-8010
Box 0560, UCSF
San Francisco, CA 94143-0560

View on UCSF Profiles

Cancer Center Membership

Program Member » Cancer Control

Additional Websites


Education

Johns Hopkins University; Baltimore, Maryland, BA, 1979-83, Biology
University of Pennsylvania; Philadelphia, MD, 1983-88, Medicine
UC, San Francisco, 1988-89, Medicine - Internship
UC, San Francisco, 1989-91, Medicine - Residency 
UC, San Francisco, 1991-92, Medicine - Chief Residency
UC, Berkeley, MPH, 1992-93, Epidemiology
UC, San Francisco, 1993-97, Infectious Diseases - Fellowship
UC, San Francisco, 1993-97, AIDS Prevention - Fellowship
 

Professional Experience

  • 1997-2003
    Assistant Professor of Epidemiology and Biostatistics, UCSF
  • 2003-2009
    Associate Professor of Epidemiology and Biostatistics, UCSF
  • 2009-present
    Professor of Epidemiology and Biostatistics, UCSF
  • 1997-present
    Attending Physician, San Francisco General Hospital
  • 1997-1999
    Co-Director, Advanced Training in Clinical Research (ATCR) Program, UCSF
  • 2000-2006
    Co-Director, NIH K30-sponsored Training in Clinical Research (TICR) Program, UCSF
  • 2000-present
    Director, Advanced Training in Clinical Research (ATCR) Certificate Program, UCSF
  • 2001-present
    Director, Master’s Degree Graduate Program in Clinical Research, UCSF
  • 2006-present
    Director, NIH CTSA-sponsored Training in Clinical Research (TICR) Graduate Program, UCSF

Honors & Awards


  • 1982
    Phi Beta Kappa
  • 1988
    Alpha Omega Alpha
  • 1988
    Merck Manual Award, University of Pennsylvania School of Medicine
  • 1989
    Diplomate, National Board of Medical Examiners
  • 1991
    Diplomate, American Board of Internal Medicine
  • 1996
    Diplomate, American Board of Internal Medicine, Subspecialty in Infectious Diseases
  • 1998
    New Investigator Award, UCSF Center for AIDS Research (CFAR)
  • 2009
    Stephen B. Hulley Award for Excellence in Instruction in Methods of Clinical Research at UCSF

Selected Publications

  1. Hunt PW, Sinclair E, Rodriguez B, Shive C, Clagett B, Funderburg N, Robinson J, Huang Y, Epling L, Martin JN, Deeks SG, Meinert CL, Van Natta ML, Jabs DA, Lederman MM. Gut epithelial barrier dysfunction and innate immune activation predict mortality in treated HIV infection. J Infect Dis. 2014 Oct 15; 210(8):1228-38.
    View on PubMed
  2. Byakwaga H, Boum Y, Huang Y, Muzoora C, Kembabazi A, Weiser SD, Bennett J, Cao H, Haberer JE, Deeks SG, Bangsberg DR, McCune JM, Martin JN, Hunt PW. The kynurenine pathway of tryptophan catabolism, CD4+ T-cell recovery, and mortality among HIV-infected Ugandans initiating antiretroviral therapy. J Infect Dis. 2014 Aug 1; 210(3):383-91.
    View on PubMed
  3. Lee SA, Sinclair E, Jain V, Huang Y, Epling L, Van Natta M, Meinert CL, Martin JN, McCune JM, Deeks SG, Lederman MM, Hecht FM, Hunt PW. Low proportions of CD28- CD8+ T cells expressing CD57 can be reversed by early ART initiation and predict mortality in treated HIV infection. J Infect Dis. 2014 Aug 1; 210(3):374-82.
    View on PubMed
  4. Burbelo PD, Bayat A, Rhodes CS, Hoh R, Martin JN, Fromentin R, Chomont N, Hütter G, Kovacs JA, Deeks SG. HIV antibody characterization as a method to quantify reservoir size during curative interventions. J Infect Dis. 2014 May 15; 209(10):1613-7.
    View on PubMed
  5. Hatano H, Strain MC, Scherzer R, Bacchetti P, Wentworth D, Hoh R, Martin JN, McCune JM, Neaton JD, Tracy RP, Hsue PY, Richman DD, Deeks SG. Increase in 2-long terminal repeat circles and decrease in D-dimer after raltegravir intensification in patients with treated HIV infection: a randomized, placebo-controlled trial. J Infect Dis. 2013 Nov 1; 208(9):1436-42.
    View on PubMed
  6. Unemori P, Leslie KS, Hunt PW, Sinclair E, Epling L, Mitsuyasu R, Effros RB, Dock J, Dollard SG, Deeks SG, Martin JN, Maurer TA. Immunosenescence is associated with presence of Kaposi's sarcoma in antiretroviral treated HIV infection. AIDS. 2013 Jul 17; 27(11):1735-42.
    View on PubMed
  7. Hatano H, Jain V, Hunt PW, Lee TH, Sinclair E, Do TD, Hoh R, Martin JN, McCune JM, Hecht F, Busch MP, Deeks SG. Cell-based measures of viral persistence are associated with immune activation and programmed cell death protein 1 (PD-1)-expressing CD4+ T cells. J Infect Dis. 2013 Jul; 208(1):50-6.
    View on PubMed
  8. Semeere AS, Busakhala N, Martin JN. Impact of antiretroviral therapy on the incidence of Kaposi's sarcoma in resource-rich and resource-limited settings. Curr Opin Oncol. 2012 Sep; 24(5):522-30.
    View on PubMed
  9. Sterling TR, Lau B, Zhang J, Freeman A, Bosch RJ, Brooks JT, Deeks SG, French A, Gange S, Gebo KA, John Gill M, Horberg MA, Jacobson LP, Kirk GD, Kitahata MM, Klein MB, Martin JN, Rodriguez B, Silverberg MJ, Willig JH, Eron JJ, Goedert JJ, Hogg RS, Justice AC, McKaig RG, Napravnik S, Thorne J, Moore RD. Risk factors for tuberculosis after highly active antiretroviral therapy initiation in the United States and Canada: implications for tuberculosis screening. J Infect Dis. 2011 Sep 15; 204(6):893-901.
    View on PubMed
  10. Hunt PW, Martin JN, Sinclair E, Epling L, Teague J, Jacobson MA, Tracy RP, Corey L, Deeks SG. Valganciclovir reduces T cell activation in HIV-infected individuals with incomplete CD4+ T cell recovery on antiretroviral therapy. J Infect Dis. 2011 May 15; 203(10):1474-83.
    View on PubMed
  11. Hatano H, Hayes TL, Dahl V, Sinclair E, Lee TH, Hoh R, Lampiris H, Hunt PW, Palmer S, McCune JM, Martin JN, Busch MP, Shacklett BL, Deeks SG. A randomized, controlled trial of raltegravir intensification in antiretroviral-treated, HIV-infected patients with a suboptimal CD4+ T cell response. J Infect Dis. 2011 Apr 1; 203(7):960-8.
    View on PubMed
  12. Dollard SC, Butler LM, Jones AM, Mermin JH, Chidzonga M, Chipato T, Shiboski CH, Brander C, Mosam A, Kiepiela P, Hladik W, Martin JN. Substantial regional differences in human herpesvirus 8 seroprevalence in sub-Saharan Africa: insights on the origin of the "Kaposi's sarcoma belt". Int J Cancer. 2010 Nov 15; 127(10):2395-401.
    View on PubMed
  13. Cummins NW, Jiang W, McGinty J, Bren GD, Bosch RJ, Landay A, Deeks SG, Martin JN, Douek D, Lederman MM, Brenchley J, Badley AD. Intracellular Casp8p41 content is inversely associated with CD4 T cell count. J Infect Dis. 2010 Aug 15; 202(3):386-91.
    View on PubMed
  14. Butler LM, Dorsey G, Hladik W, Rosenthal PJ, Brander C, Neilands TB, Mbisa G, Whitby D, Kiepiela P, Mosam A, Mzolo S, Dollard SC, Martin JN. Kaposi sarcoma-associated herpesvirus (KSHV) seroprevalence in population-based samples of African children: evidence for at least 2 patterns of KSHV transmission. J Infect Dis. 2009 Aug 1; 200(3):430-8.
    View on PubMed
  15. Butler LM, Osmond DH, Jones AG, Martin JN. Use of saliva as a lubricant in anal sexual practices among homosexual men. J Acquir Immune Defic Syndr. 2009 Feb 1; 50(2):162-7.
    View on PubMed
  16. Phillips AM, Jones AG, Osmond DH, Pollack LM, Catania JA, Martin JN. Awareness of Kaposi's sarcoma-associated herpesvirus among men who have sex with men. Sex Transm Dis. 2008 Dec; 35(12):1011-4.
    View on PubMed
  17. Hsue PY, Deeks SG, Farah HH, Palav S, Ahmed SY, Schnell A, Ellman AB, Huang L, Dollard SC, Martin JN. Role of HIV and human herpesvirus-8 infection in pulmonary arterial hypertension. AIDS. 2008 Apr 23; 22(7):825-33.
    View on PubMed
  18. Hunt PW, Brenchley J, Sinclair E, McCune JM, Roland M, Page-Shafer K, Hsue P, Emu B, Krone M, Lampiris H, Douek D, Martin JN, Deeks SG. Relationship between T cell activation and CD4+ T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy. J Infect Dis. 2008 Jan 1; 197(1):126-33.
    View on PubMed
  19. Martin JN. Moving toward clarity on 2 fronts in the epidemiology of Kaposi sarcoma-associated herpesvirus infection. J Infect Dis. 2007 Jul 15; 196(2):173-5.
    View on PubMed
  20. Ray N, Harrison JE, Blackburn LA, Martin JN, Deeks SG, Doms RW. Clinical resistance to enfuvirtide does not affect susceptibility of human immunodeficiency virus type 1 to other classes of entry inhibitors. J Virol. 2007 Apr; 81(7):3240-50.
    View on PubMed

Go to UCSF Profiles, powered by CTSI